Table 2.
Comparison of ex vivo tumor uptake of 111In-labeled RLP, SP-LP, and Hybrid-LP in BALB/c nude mice bearing U-87 MG and M21 tumor xenografts at 1 and 4 hours post-injection (RLP, n=7; SP-LP, n=7; Hybrid-LP, n=10)
| % ID/g 1 hour post-injection
|
% ID/g 4 hours post-injection
|
|||||
|---|---|---|---|---|---|---|
| 111In-RLP | 111In-SP-LP | 111In-Hybrid-LP | 111In-RLP | 111In-SP-RLP | 111In-Hybrid-LP | |
| U-87 MG | 1.55±0.27 | 1.04±0.34 | 1.03±0.61 | 1.05±0.56 | 1.27±0.32 | 1.23±0.28 |
| M21 | – | – | 0.55±0.10 | – | – | 0.59±0.86 |
Note: Values are expressed as % ID/g (means ± standard deviation) at one and 4 hours post-injection.
Abbreviations: % ID/g, percentage injected dose per gram of tissue; 111In, indium-111; Hybrid-LP, liposomal nanoparticle carrying an RGD and SP building block; LP, liposome; NoTarget-LP, liposomal nanoparticle with no targeting sequence; RGD, arginine-glycine-aspartic acid; RLP, liposomal nanoparticle carrying an RGD building block; SP, substance P; SP-LP, liposomal nanoparticle carrying an SP building block.